Literature DB >> 25956992

Stabilization of Alpha-Synuclein Oligomers In Vitro by the Neurotransmitters, Dopamine and Norepinephrine: The Effect of Oxidized Catecholamines.

Andrew F Fischer1, Kathryn Mansfield Matera.   

Abstract

Aggregation of the protein alpha-synuclein has been identified in the pathogenesis of Parkinson's disease and is initiated by the folding of the protein monomer into an amyloid form of insoluble fibrils. The neurotransmitters dopamine and norepinephrine have been shown to both inhibit the formation of these fibrils and disaggregate existing fibrils, yielding the more toxic oligomeric form of α-synuclein. This study characterizes the stable oligomers formed through the aggregation and disaggregation processes in the presence of these catecholamines, and suggests differences in oligomer formation depending on the extent of oxidation of the neurotransmitter at the time of oligomerization. Unique oligomers are also stabilized, likely formed from the aggregation of monomeric α-synuclein and a proteolytic fragment of α-synuclein; however, proteolytic fragments do not form as readily in the presence of these neurotransmitters. These findings suggest novel pathways for the formation of α-synuclein oligomers in the presence of neurotransmitters, particularly oxidized forms.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25956992     DOI: 10.1007/s11064-015-1597-y

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  40 in total

1.  Autoproteolytic fragments are intermediates in the oligomerization/aggregation of the Parkinson's disease protein alpha-synuclein as revealed by ion mobility mass spectrometry.

Authors:  Camelia Vlad; Kathrin Lindner; Christiaan Karreman; Stefan Schildknecht; Marcel Leist; Nick Tomczyk; John Rontree; James Langridge; Karin Danzer; Thomas Ciossek; Alina Petre; Michael L Gross; Bastian Hengerer; Michael Przybylski
Journal:  Chembiochem       Date:  2011-11-07       Impact factor: 3.164

2.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

3.  In vivo demonstration that alpha-synuclein oligomers are toxic.

Authors:  Beate Winner; Roberto Jappelli; Samir K Maji; Paula A Desplats; Leah Boyer; Stefan Aigner; Claudia Hetzer; Thomas Loher; Marçal Vilar; Silvia Campioni; Christos Tzitzilonis; Alice Soragni; Sebastian Jessberger; Helena Mira; Antonella Consiglio; Emiley Pham; Eliezer Masliah; Fred H Gage; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-15       Impact factor: 11.205

4.  Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Authors:  K A Conway; J C Rochet; R M Bieganski; P T Lansbury
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

Review 5.  Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.

Authors:  Michael J Volles; Peter T Lansbury
Journal:  Biochemistry       Date:  2003-07-08       Impact factor: 3.162

Review 6.  Modulation of alpha-synuclein aggregation by dopamine: a review.

Authors:  Su Ling Leong; Roberto Cappai; Kevin Jeffrey Barnham; Chi Le Lan Pham
Journal:  Neurochem Res       Date:  2009-05-15       Impact factor: 3.996

Review 7.  Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications.

Authors:  Daniel M Skovronsky; Virginia M-Y Lee; John Q Trojanowski
Journal:  Annu Rev Pathol       Date:  2006       Impact factor: 23.472

Review 8.  Multiple dopamine functions at different time courses.

Authors:  Wolfram Schultz
Journal:  Annu Rev Neurosci       Date:  2007       Impact factor: 12.449

9.  Human SOD2 modification by dopamine quinones affects enzymatic activity by promoting its aggregation: possible implications for Parkinson's disease.

Authors:  Elisa Belluzzi; Marco Bisaglia; Elisabetta Lazzarini; Leandro C Tabares; Mariano Beltramini; Luigi Bubacco
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

Review 10.  Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.

Authors:  Jean-Christophe Rochet; Tiago Fleming Outeiro; Kelly A Conway; Tomas T Ding; Michael J Volles; Hilal A Lashuel; Robert M Bieganski; Susan L Lindquist; Peter T Lansbury
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 2.866

View more
  3 in total

1.  Enhanced mitochondrial inhibition by 3,4-dihydroxyphenyl-acetaldehyde (DOPAL)-oligomerized α-synuclein.

Authors:  Theodore A Sarafian; Amneh Yacoub; Anastasia Kunz; Burkan Aranki; Grigor Serobyan; Whitaker Cohn; Julian P Whitelegge; Joseph B Watson
Journal:  J Neurosci Res       Date:  2019-08-16       Impact factor: 4.164

2.  Impaired Phasic Discharge of Locus Coeruleus Neurons Based on Persistent High Tonic Discharge-A New Hypothesis With Potential Implications for Neurodegenerative Diseases.

Authors:  Kathrin Janitzky
Journal:  Front Neurol       Date:  2020-05-12       Impact factor: 4.003

3.  A hyperbranched dopamine-containing PEG-based polymer for the inhibition of α-synuclein fibrillation.

Authors:  Leonid Breydo; Ben Newland; Hong Zhang; Anne Rosser; Carsten Werner; Vladimir N Uversky; Wenxin Wang
Journal:  Biochem Biophys Res Commun       Date:  2015-12-18       Impact factor: 3.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.